Strive (ASST) has drawn fresh attention after recent trading left the stock well below its past year level, with both short term moves and longer term declines prompting investors to reassess risk and potential reward.

At the latest share price of $11.34, Strive’s 7 day share price return is down 23.64% and the 30 day share price return is down 36.36%, while the 1 year total shareholder return has declined 85.50%. This suggests recent momentum has been fading as investors reassess both upside potential and risk.

If you are weighing what might offer a different return profile, this could be a good moment to look beyond Strive and check out 39 healthcare AI stocks.

With Strive’s share price under pressure despite a published analyst price target of $29.60, the key question now is whether the recent weakness points to an undervalued stock or to a market that is already discounting future growth.

Preferred Price-to-Book of 1.2x: Is it justified?

With Strive trading at $11.34 and a P/B ratio of 1.2x, the stock sits at a valuation that is well below both its industry and peer averages.

The P/B ratio compares the market value of Strive’s equity to its book value on the balance sheet. This can be a useful lens for companies that are currently unprofitable but still building assets and franchise value. In this case, the focus is less on current earnings and more on what investors are willing to pay for each dollar of net assets.

For Strive, this lower P/B level exists alongside a business profile that includes current losses, a reported loss of $700.519,000 on revenue of $7.071m, and forecasts that point to revenue and earnings growth over time. That combination can suggest the market is cautious about execution and profitability, even as analysts expect the company to move toward profit in the coming years.

Compared to the US Medical Equipment industry average P/B of 2.4x and a peer average of 7.1x, Strive’s 1.2x ratio is markedly lower, which signals that the market is assigning a sizeable discount relative to similar stocks.

Result: Price-to-book of 1.2x (ABOUT RIGHT).

However, Strive still carries clear risks, including ongoing losses of $700.519m on $7.071m in revenue, and a long term shareholder return that has declined 93.48% over 3 years.

Next Steps

Given the mix of caution and optimism around Strive, it makes sense to act promptly, review the underlying data, and form your own judgment using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Strive?

If Strive has prompted you to rethink your portfolio, this can be a useful moment to broaden your watchlist and compare it with other potential opportunities.

• Target potential mispricing by scanning 44 high quality undervalued stocks that combine business fundamentals with share prices that may not fully reflect their financial strength.
• Support your income stream by reviewing 8 dividend fortresses that focus on higher yielding companies with an emphasis on stability.
• Manage portfolio risk by checking 72 resilient stocks with low risk scores that prioritize resilience and more measured risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.